AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03110068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced ultrasound
Description: The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
Study NCT03110068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced computed tomography
Description: The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
Study NCT01530282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive method
Description: Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
Study NCT01530282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive method
Description: Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
Study NCT03742206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasacral Transcutaneous Electrical Stimulation
Description: Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
Study NCT00539227 — intervention group
Intervention type: PROCEDURE
Intervention: NAC Sparing Mastectomy
Description: A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
Study NCT00539227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking about 20-30 minutes to complete.
Study NCT04276363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Professional Learning plus ParentCorps
Description: led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
Study NCT04276363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Professional Learning only
Description: Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
Study NCT04276363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspire Professional Learning
Description: Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
Study NCT04555850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
Study NCT04555850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
Study NCT01031459 — intervention group
Intervention type: DRUG
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: Telephone survey of all patients.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 6g IV over 6 hours
Description: Meropenem 6g intravenously over 6 hours once daily on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1g IM
Description: Ertapenem 1g intramuscularly once daily on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 3g IV
Description: Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1g IV
Description: Ertapenem 1g intravenously once daily on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
Study NCT04608305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 top-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
Study NCT03742206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation
Description: Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
Study NCT04780945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional RAD51 assay
Description: ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 35 mg/kg
Description: Rifampicin 35 mg/kg once daily on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 6g IV over 60 minutes
Description: Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275
Description: Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 4g IV
Description: Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
Study NCT05896930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA once daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
Study NCT01844739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 4% Gel
Description: Applied topically twice daily
Study NCT01844739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically twice daily
Study NCT04780945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: 300 mg bid
Study NCT02693236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-transfected autologous DC vaccine plus CIK cells
Study NCT00554463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
Study NCT00554463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg via subcutaneous injection days 46 and 67
Study NCT00554463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
Study NCT00554463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
Study NCT00554463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
Study NCT04263402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
Study NCT04263402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
Study NCT01715064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of moderate-intensity exercise
Study NCT01431859 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergovit Birch pollen
Description: Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
Study NCT01431859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
Study NCT03265613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
Study NCT03128359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo PBSC HCT
Study NCT01168206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TK3
Description: Tritofano 160mg / Timina140mg and starch 150 mg
Study NCT01168206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 capsule, 3 times per day
Description: Placebo
Study NCT02530476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
Study NCT00130039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
Study NCT00130039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
Study NCT00642707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140 (humanized monoclonal antibody to CCR5)
Study NCT00642707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT05353413 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neuroimaging
Description: Magnetic resonance diffusion tensor imaging of the brain
Study NCT05353413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: Magnetic resonance diffusion tensor imaging of the brain
Study NCT05353413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VEP - visual evoked potential
Description: Electrophysiology of the visual pathway.
Study NCT05353413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VEP - visual evoked potential
Description: Electrophysiology of the visual pathway.
Study NCT05353413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ophthalmology examination.
Description: Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
Study NCT05353413 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ophthalmology examination.
Description: Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
Study NCT03165786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FREE
Description: Cognitive behavioral therapy with real-time continuous glucose monitoring.
Study NCT01562886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 26mg
Study NCT01165125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FF / GW642444
Description: 200mcg/25mcg Novel DPI
Study NCT01165125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: 400mcg overencapsulated tablets
Study NCT01165125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole (placebo to match)
Description: placebo to match overencapsulated tablets
Study NCT01983592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic medicine
Description: Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
Study NCT01983592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unmedicated lactose/sucrose globule
Study NCT03420144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
Study NCT03420144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
Study NCT03693144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full LIITA3H App
Description: This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
Study NCT03693144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial LIITA3H App
Description: This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
Study NCT03693144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LIITA3H Location only
Description: This is a version of the LIITA3H mobile app that will only track participants' location.
Study NCT02861339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opthalmologic measure with DM OPD scan III (Nidek)
Description: Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
Study NCT02607410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Study NCT02607410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Study NCT04160312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitopure™ (Proprietary Urolithin A)
Description: Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
Study NCT04160312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: 100% Pomegranate juice (approximately 1 glass equivalent)
Study NCT00954161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping behaviour curriculum
Description: The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
Study NCT00954161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First aid only curriculum
Description: Two hours training on first aid for alcohol and drug incidents
Study NCT01545596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notification Group
Description: Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
Study NCT03306433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UDMA-K18 smooth surface sealant
Description: The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
Study NCT03306433 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: UDMA-K18 smooth surface sealant
Description: The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
Study NCT04335448 — intervention group
Intervention type: OTHER
Intervention: No intervention is planed
Description: No intervention is planed
Study NCT04171505 — intervention group
Intervention type: DRUG
Intervention: HPV vaccine
Description: . Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account.
Study NCT03135431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Salpingectomy
Description: Surgical removal of entire fallopian tubes
Study NCT03135431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Tubal Ligation
Description: Surgical tying, cutting, or removal of a portion of the fallopian tubes
Study NCT05214066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
Study NCT02990975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study NCT00711152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol-driven care under JADE Program
Description: The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
Study NCT00711152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol-driven care under JADE Program
Description: The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
Study NCT00711152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional support by CHW
Description: Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.